Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to Johnson & Johnson.

Kelsey Warren KWarren6@its.jnj.com  609 218 4053 Investor contact: Lauren Johnson investor-relations@its.jnj.com ...

It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...

Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD.